AstraZeneca PLC and Moderna, Inc. both announced that their COVID-19 vaccines show signs of efficacy against the Delta (B.1.617.2) and other SARS-CoV-2 variants of concern as evidence mounts that Delta in particular is able to evade protection by Moderna’s mRNA-1273 and Pfizer Inc./BioNTech SE’s BNT162b2. The question now is whether booster shots will provide protection from the variant, first identified in India, as well as other more virulent strains.
Vaccines Show Signs Of Efficacy Against Delta Variant, But Is It Enough?
AstraZeneca and Moderna disclosed clinical and preclinical evidence that their COVID-19 vaccines, Vaxzevria and mRNA-1273, provide protection against the B.1.617.2 strain.